medigraphic.com
Colegio de Medicina Interna de México.

2020, Number 4

<< Back Next >>

Med Int Mex 2020; 36 (4)

Variability of hemoglobin levels and risk of mortality in patients with heart failure: survival analysis

García-Arias MR, Ramírez-García L, Gonzaga-López TI, Ramos-Arrieta MÁ, López-Cisneros G

Language: Spanish
References: 15
Page: 467-475
PDF size: 207.31 Kb.


ABSTRACT

Background: Heart failure is a global problem, with elevated morbidity and mortality. Thus, the study of independent risk factors is relevant.
Objective: To determine if the decrease of 2 g/dL or more of hemoglobin levels is associated with higher mortality in patients with heart failure.
Material and Method: A retrospective, longitudinal and observational study performed at the Central North Hospital of Pemex, Mexico, from 2010 to 2015, including patients hospitalized for heart failure, with follow-up of hemoglobin levels at the beginning and until their death or at the end of the study (February 2019). Patients were classified into three groups according to hemoglobin variability. Group 1: negative variability: decrease of hemoglobin 2 g/dL or more. Group 2: no variability: changes in hemoglobin from › 1.9 a to ‹ 1.9 g/dL. Group 3: positive variability: increase of hemoglobin 2 g/dL or more.
Results: There were included 179 patients. According to the univariate analysis: in group 1 was obtained a median survival of 18 months; in group 2 a median survival of 53 months; median survival was not achieved in group 3.
Conclusions: The decrease of 2 g/dL or more of hemoglobin is an independent risk factor for mortality in patients with heart failure.


REFERENCES

  1. Ponikowski P, A Voors A, D Anker S, Bueno H, Cleland J, Coats A, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution. Eur Heart J 2016; 37(27): 2129-2200. https://doi.org/10.1093/ eurheartj/ehw128

  2. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet 2014; 383(9921): 999-1008. doi: 10.1016/S0140-6736(13)61752-3

  3. Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 2011; 89(2): 265-272. doi: 10.1093/cvr/cvq308

  4. Belevych AE, Terentyev D, Terentyeva R, Nishijima Y, Sridhar A, Hamlin RL, et al. The relationship between arrhythmogenesis and impaired contractility in heart failure: Role of altered ryanodine receptor function. Cardiovasc Res 2011; 90(3): 493-502. doi: 10.1093/cvr/cvr025.

  5. Respress JL, Van Oort RJ, Li N, Rolim N, Dixit SS, Dealmeida A, et al. Role of RyR2 phosphorylation at S2814 during heart failure progression. Circ Res 2012; 110(11): 1474-1483. doi: 10.1161/CIRCRESAHA.112.268094

  6. Chen Y, Escoubet B, Prunier F, Amour J, Simonides WS, Vivien B, et al. Constitutive cardiac 6overexpression of sarcoplasmic/ endoplasmic reticulum Ca 2+-ATPase delays myocardial failure after myocardial infarction in rats at a cost of increased acute arrhythmias. Circulation 2004; 109(15): 1898-1903. doi: 10.1161/01.CIR.0000124230.60028.42

  7. Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. N Engl J Med 2011; 364(17): 1643-1656.

  8. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: Approaches and considerations. Nat Rev Genet 2012; 13(5): 358-369. doi: 10.1038/nrg3198

  9. Metra M, Teerlink JR. Heart failure. Lancet 2017; 390(10106): 1981-1995. doi: 10.1016/S0140-6736(17)31071-1

  10. Peacock WF, Braunwald E, Abraham W, Albert N, Burnett J, Christenson R, et al. National heart, lung, and blood institute working group on emergency department management of acute heart failure: Research challenges and opportunities. J Am Coll Cardiol 2010; 56(5): 343-351. doi: 10.1016/j.jacc.2010.03.051

  11. Adams K, Patterson J, Oren R, Mehra M, O’Connor C, Piña I, et al. Congestive Heart Failure Prospective assessment of the occurrence of anemia in patients with heart failure: Results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. Congest Hear Fail 2009; 157(5): 926-932. doi: 10.1016/j.ahj.2009.01.012

  12. Grote Beverborg N, et al. Anemia in heart failure. Still relevant? JACC Hear Fail 2018; 6(3): 201-208. DOI: 10.1016/j. jchf.2017.08.023

  13. Abebe TB, Gebreyohannes EA, Bhagavathula AS, Tefera YG, Abegaz TM. Anemia in severe heart failure patients: Does it predict prognosis? BMC Cardiovasc Disord 2017; 17(1): 1-7. doi: 10.1186/s12872-017-0680-5

  14. Ruiz Giolo S, Krieger JE, Mansur AJ, Pereira AC. Survival analysis of patients with heart failure: Implications of time-varying regression effects in modeling mortality. PLoS One 2012; 7(6): 1-9. https://doi.org/10.1371/journal. pone.0037392

  15. Varadarajan P, Gandhi S, Sharma S, Umakanthan B, Pai RG. Prognostic significance of hemoglobin level in congestive heart failure patients with normal compared to reduced ejection fraction. Clin Cardiol 2006; 29(10): 444-449. doi: 10.1002/clc.4960291006




2020     |     www.medigraphic.com